EMEA-001521-PIP01-13-M05

Key facts

Invented name
Reblozyl
Active substance
Luspatercept
Therapeutic area
Haematology-Hemostaseology
Decision number
P/0037/2021
PIP number
EMEA-001521-PIP01-13-M05
Pharmaceutical form(s)
Powder for solution for injection
Condition(s) / indication(s)
  • Treatment of beta-thalassaemia
  • Treatment of myelodysplastic syndromes
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Bristol-Myers Squibb Pharma EEIG

Email: medinfo.emea@celgene.com
Tel. +41327298500
 

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating
Average
1 rating